Sanofi (SNY,SAN.PA) said the European Commission has granted a conditional marketing authorisation for Rezurock or belumosudil for the treatment of chronic graft-versus-host disease in adults and in children aged 12 years and older with a body weight of at least 40 kg. The conditional marketing authorisation is contingent on completion of a confirmatory, randomised, controlled study. This follows the positive opinion by the CHMP issued on 30 January 2026.
The company said the approval is based on safety and efficacy results from several clinical studies and real-world evidence. In addition to the EU, Rezurock is approved in 20 countries.
At last close, shares of Sanofi were trading at 81.90 euros, down 0.11%.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.